pds0101

Cervical Cancer

Weill Medical College of Cornell UniversityUNKNOWNPhase 2Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 65/ 100

Competitive context

158 Active assets in the Cervical Cancer cohort.

Asset / Sponsor	Phase	Rating
Vinorelbine Ditartrate UNICANCER	Phase 2	BBB
Tisotumab Vedotin Seagen Inc.	Phase 2	BB
Cyclophosphamide Merck Sharp & Dohme LLC	Phase 3	B
Technetium-99 Institut de Cancérologie de Lorraine	Phase 3	B
Pembrolizumab Merck Sharp & Dohme LLC	Phase 3	B

View all 50 →

Same molecule, other indications

pds0101 is also rated in:

anal carcinomaActive

B

Indicative · Phase 2

58 / 100

HIV infectious diseaseActive

CCC

Indicative · Phase 2

53 / 100

oropharyngeal carcinomaDormant

CCC

Indicative · Phase 1/2

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.